Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | NSD2 | O96028 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588953 | 0.90 | KDM4E (0.47) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL13928084 | 0.81 | CES2 (0.53) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL79009 | 0.79 | CES2 (1.00) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL7896994 | 0.78 | CES2 (0.60) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL13928036 | 0.78 | CES2 (0.56) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL20867386 | 0.76 | CES2 (0.53) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL1392670 | 0.76 | CES1 (0.47) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL2575338 | 0.76 | CES1 (0.57) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL13453022 | 0.73 | CES2 (0.53) | CES2BCHEACHECES1NSD2 | |
| SCHEMBL21327556 | 0.71 | CES2 (0.90) | CES2BCHEACHECES1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TLR7, C5, CD4 | CES2 2834/4885BCHE 1739/4885ACHE 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.